<DOC>
	<DOCNO>NCT01087476</DOCNO>
	<brief_summary>Background . Mucositis complication chemotherapy effective treatment . Aim.To evaluate efficacy sub-microbial dos doxycycline hyclate preventing development oral mucositis patient acute leukemia ( AL ) treat induction chemotherapy . Hypothesis . Doxycycline hyclate administration sub-microbial dosage reduce incidence oral mucositis patient AL receive induction chemotherapy . Methods . Double-blind , randomize , placebo-controlled clinical trial . At Cancer National Institute ( INCan ) , adult patient ( &gt; 18 year age ) acute leukemia recent diagnosis , schedule receive induction chemotherapy enrol study . Written informed consent patient obtain precede inclusion study . At baseline 3-times per week , 21-days , patient oral examination perform use Oral Mucositis Assessment Scale ( OMAS ) , oral pain , difficulty swallow , salivary flow measurement record . A sample size 164 subject calculate , 74 subject arm study . The primary end point study evaluate efficacy proportion patient treat doxycycline placebo without oral lesion associate OM , 21 day follow-up . Efficacy evaluate proportion complete response ( CR ) significantly high proportion event placebo group . Additional secondary endpoint partial resolution oral lesion , incidence infection mortality study group 21 day follow-up . Results analyze use Chi-squared test Wilcoxon-Mann-Whitney rank sum test .</brief_summary>
	<brief_title>Double-blind-randomized , Placebo Controlled Trial Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate</brief_title>
	<detailed_description>Background . Mucositis complication chemotherapy effective treatment . Aim.To evaluate efficacy sub-microbial dos doxycycline hyclate preventing development oral mucositis patient acute leukemia ( AL ) treat induction chemotherapy . Hypothesis . Doxycycline hyclate administration sub-microbial dosage reduce incidence oral mucositis patient AL receive induction chemotherapy . Methods . Double-blind , randomize , placebo-controlled clinical trial . At Cancer National Institute ( INCan ) , adult patient ( &gt; 18 year age ) acute leukemia recent diagnosis , schedule receive induction chemotherapy enrol study . Written informed consent patient obtain precede inclusion study . Stratification accord type acute leukemia ( myeloblastic lymphoblastic ) do . Random number table use balance every four subject ; cod box utilized preserve double blinding . Patients randomly assign receive either sub-microbial dose doxycycline hyclate placebo ( 50 mg per day ) , immediately initiation induction chemotherapy daily follow 21 day chemotherapy . At baseline 3-times per week , 21-days , patient oral examination perform use Oral Mucositis Assessment Scale ( OMAS ) . Also oral pain difficulty swallow record use visual analogue scale . Also visit , salivary flow measurement ( Schirmer 's test modify version ) do . The OMAS system validate index evaluate severity oral mucositis measure degree ulceration/pseudomembrane erythema nine sit oral mucosa ( upper low lip , right leave inner cheek , right leave ventral lateral tongue , floor mouth , soft palate/fauces hard palate ) . At site , erythema evaluate use 3-point scale ( 0=none , 1=mild/moderate , 2=severe ) , ulceration/pseudomembrane formation evaluate use 4-point scale ( 0=none , 1=cumulative surface area &lt; 1 cm2 , 2=cumulative surface area 1-3 cm2 , 3=cumulative surface area &gt; 3 cm2 ) . The value OMAS obtain sum erythema ulceration/pseudomembrane sub-scores site average score across affect site . In order rule oral candidosis ( OC ) , definitive diagnosis OC require identification pseudohyphae exfoliative cytology sample stain periodic acid Schiff . Likewise , clinical diagnosis herpes simplex virus ( HSV ) induce oral lesion confirm virus-infected cell demonstrate cytologic smear stain Papanicolaou , and/or clinical response systemic antiviral therapy acyclovir . A sample size 164 subject calculate , 74 subject arm study . This estimate base incidence OM high 40 % patient AL , consider reduction half ( 20 % ) , assume alpha value 0.05 ( one-sided ) minimum statistical power 0.80 . The efficacy primary end point study proportion patient treat doxycycline placebo without oral lesion associate OM , 21 day follow-up . Efficacy evaluate proportion complete response ( CR ) significantly high proportion event placebo group . Additional secondary endpoint partial resolution oral lesion , incidence infection mortality study group 21 day follow-up . Statistical analysis . Results analyse use Chi-squared test Wilcoxon-Mann-Whitney rank sum test .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Adult patient ( &gt; 18 year age ) acute leukemia recent diagnosis , schedule receive induction chemotherapy . Capacity give write informed consent . Ability attend followup visit . Patients allergy intolerance tetracycline Patients acute chronic renal insufficiency ( basal blood creatinine &gt; 1.9 mg/dl ) Patients contraindication oral administration drug . Patients active septic process consider resolve less 7 day start chemotherapy . Patients required tetracycline administration 28 day previous randomization . Adult patient acute leukemia schedule undergo stemcell transplantation follow two week . Adult patient hematological cancer previous radiotherapy may affect salivary gland . Inability authorize write informed consent . Exclusion criteria Patients start chemotherapy 12 hour assign treatment . Patients receive less 10 dos ( 5 day ) assign treatment . Requirement receive ergot derivates . Patients require administration acitretin/isotretinoin/tretinoin Patients receive photosensitive drug study period ( hydroxyquinone/retinoids methoxsalen )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>oral mucositis</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>salivary flow .</keyword>
</DOC>